| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3282 | 2013 |
| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2174 | 2016 |
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized MF Van Delft, AH Wei, KD Mason, CJ Vandenberg, L Chen, PE Czabotar, ... Cancer cell 10 (5), 389-399, 2006 | 1488 | 2006 |
| Programmed anuclear cell death delimits platelet life span KD Mason, MR Carpinelli, JI Fletcher, JE Collinge, AA Hilton, S Ellis, ... Cell 128 (6), 1173-1186, 2007 | 1252 | 2007 |
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models A Kotschy, Z Szlavik, J Murray, J Davidson, AL Maragno, ... Nature 538 (7626), 477-482, 2016 | 1099 | 2016 |
| SOCS3 negatively regulates IL-6 signaling in vivo BA Croker, DL Krebs, JG Zhang, S Wormald, TA Willson, EG Stanley, ... Nature immunology 4 (6), 540-545, 2003 | 1023 | 2003 |
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ... The lancet oncology 17 (6), 768-778, 2016 | 976 | 2016 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488-496, 2012 | 974 | 2012 |
| The genomic landscape of hypodiploid acute lymphoblastic leukemia L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ... Nature genetics 45 (3), 242-252, 2013 | 831 | 2013 |
| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826-833, 2017 | 806 | 2017 |
| Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl WS Alexander, AW Roberts, NA Nicola, R Li, D Metcalf | 686 | 1996 |
| Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense AW Roberts, C Kim, L Zhen, JB Lowe, R Kapur, B Petryniak, A Spaetti, ... Immunity 10 (2), 183-196, 1999 | 674 | 1999 |
| RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis JA Rickard, JA O’Donnell, JM Evans, N Lalaoui, AR Poh, TW Rogers, ... Cell 157 (5), 1175-1188, 2014 | 621 | 2014 |
| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 567 | 2020 |
| Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin S Kimura, AW Roberts, D Metcalf, WS Alexander Proceedings of the National Academy of Sciences 95 (3), 1195-1200, 1998 | 494 | 1998 |
| G-CSF: a key regulator of neutrophil production, but that's not all! AW Roberts Growth factors 23 (1), 33-41, 2005 | 461 | 2005 |
| Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma CS Tam, MA Anderson, C Pott, R Agarwal, S Handunnetti, RJ Hicks, ... New England journal of medicine 378 (13), 1211-1223, 2018 | 453 | 2018 |
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation … A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, ... Journal of Clinical Oncology 27 (11), 1788-1793, 2009 | 446 | 2009 |
| Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia P Blombery, MA Anderson, J Gong, R Thijssen, RW Birkinshaw, ... Cancer discovery 9 (3), 342-353, 2019 | 436 | 2019 |
| AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies S Caenepeel, SP Brown, B Belmontes, G Moody, KS Keegan, D Chui, ... Cancer discovery 8 (12), 1582-1597, 2018 | 414 | 2018 |
